The Alan Turing Institute, based in London, has appointed OIA’s Founder and CEO, Dr Hector Zenil, as a senior researcher and policy advisor on Artificial Intelligence for Scientific Discovery. In this role, supported by the United States Department of Defense reporting to research officials at the Pentagon and the White House, Dr Zenil has been commissioned to lead and oversee the compilation of an international report to advise the U.K. and its allies on the use and future of A.I. in scientific discovery. Its particular focus will be A.I. capable of making scientific discoveries meriting a Nobel Prize in the next 30 years without the help of human scientists but with a view to accelerate science to find solutions to some of the most pressing human challenges, such as climate change, antibiotic resistance, cancer and chronic diseases.
Since 2016, Dr. Zenil co-leads the Algorithmic Dynamics Lab at the Unit of Computational Medicine at the Karolinska Institute in Sweden, the institution that awards the Nobel Prize in Physiology or Medicine. After joining the University of Oxford as senior researcher and faculty member, Dr. Zenil founded Oxford Immune Algorithmics (OIA). OIA are the creators of Algocyte, an AI solution that democratises healthcare by advancing precision and predictive medicine harnessing the power of responsible computational intelligence and the immune system.
Founded in 2015, the Alan Turing Institute is the United Kingdom’s national data science and artificial intelligence institute. Named after Alan Turing, the British mathematician and computing pioneer, the institute is a joint venture among the Universities of Cambridge, Edinburgh, Oxford, Warwick and UCL. The Institute’s Director and Chief Executive, appointed in 2018, is Sir Adrian Smith, who also serves as President of the Royal Society. The Chair of the Alan Turing Institute is Howard Covington.
Oxford Immune Algorithmics (OIA) is an award-winning Bio-Tech company incubated by the University of Oxford with a vision to democratise healthcare so as to rid the world of preventable diseases. To do this, OIA harnesses the power of an advanced type of augmented AI that has human-like reasoning capabilities to monitor people’s immune systems. OIA operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.